Quality & Regulatory Expectations of Outsourcing Oversight Nicky Dodsworth, VP Global Quality Assurance.

Slides:



Advertisements
Similar presentations
CMRSC Division of Hematology/Oncology
Advertisements

Project Quality Plans Gillian Sandilands Director of Quality
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Briefing on MHRA routine inspection of non-commercial clinical trials
Managing the Health and Safety of Contractors
Tips to a Successful Monitoring Visit
Radiopharmaceutical Production
HOT TOPICS ARCHIVING OR HOW NOT TO DUMP YOUR RUBBISH!
USG INFORMATION SECURITY PROGRAM AUDIT: ACHIEVING SUCCESSFUL AUDIT OUTCOMES Cara King Senior IT Auditor, OIAC.
EPA Regions 9 & 10 and The Federal Network for Sustainability 2005
Enhancing the CRO-Sponsor Collaboration to Ensure High Quality of Clinical Data May 17,2011 | Beijing, China Charles Yan, PhD Shanghai Clinical Research.
Quality Management within the Clinical Research Process
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
QA Programs for Local Health Departments
The key steps in an annual cycle Produce the annual work programme Create an annual Internal Audit plan for approval by the Audit Committee, typically.
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
Monitoring and Auditing
Practical Effective Steps to Improve Trial QUALITY from Audit/Inspections findings Cancer Clinical Trials Unit Scotland A NCRI Accredited Cancer Trials.
Cheryl McCarthy Manager, Quality Assurance MBC Session October 3, 2008 GCP Compliance in our Vendors.
Coping with Electronic Records Setting Standards for Private Sector E-records Retention.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi.
What SMS means for an Operator’s relationship with the CAA
FPSC Safety, LLC ISO AUDIT.
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
Vendor Risk: Effective Management is Essential
Internal Auditing and Outsourcing
Quality Assurance in Bio-availability / Bio-equivalence studies. DR
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
ASEAN GMP TRAINING MODULE PERSONNEL
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.
World Health Organization
Building Quality Assurance into Clinical Trials. Objectives for Today: Define Quality in Research Describe How to Initiate Corrective and Preventative.
Module J Audits and Inspections Patricia E. Koziol 1Module J Final Version 1-May-2010.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
RAISING THE BAR Meeting CSA Guidelines And Preparing for Health Canada
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Lecture #9 Project Quality Management Quality Processes- Quality Assurance and Quality Control Ghazala Amin.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Safety Auditors Conference 2005 A Practical Approach…….
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Conducting Clinical Risk Assessments And Implementing Compliance Practices Jane L. Stratton Chiron Corporation VP/Associate General Counsel Chief Compliance.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Inspection Part III.
Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.
A QUALITY IMPROVEMENT TOOL
Please use the following two slides as a template for your presentation at NES. A Property Management Internal Audit (PMIA) Program The Purpose & The Plan.
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
Welcome. Contents: 1.Organization’s Policies & Procedure 2.Internal Controls 3.Manager’s Financial Role 4.Procurement Process 5.Monthly Financial Report.
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Briefing on MHRA routine inspection of non-commercial clinical trials
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
Responsibilities of Sponsor, Investigator and Monitor
MHRA GMP Inspection Deficiency Data Trend 2016
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Gilbert Ogetii KEMRI-Wellcome Trust Research Programme Kilifi, Kenya
Pharmacovigilance inspections: what HPRA expects
Radiopharmaceutical Production
S A Overarching SOPs Funding Secured Training Records
Presentation transcript:

Quality & Regulatory Expectations of Outsourcing Oversight Nicky Dodsworth, VP Global Quality Assurance

Topics  Interesting Facts & Figures  The Problem  What are the Regulations?  Vendor Assessment Processes  Importance of Risk Assessments  QA’s role in Assessment/Evaluation  What is the Focus of an Audit?  Type of Audits/ SOPs/ Audit processes  What do Inspectors/Auditors find?/ Common Failures

Interesting Facts and Figures Pharmaceutical companies currently contract out 20% - 100% of their R&D. The clinical research market is growing rapidly, with the proportion of the market outsourced to CROs having grown from $1 billion in 1992 to over $25 billion now. According to the Tufts Center, clinical trials conducted by CROs are completed an average of 30% more quickly than those conducted in-house. This results in time saving of some months; $120 - $150 million (£1 m/ day).

The Problem

What Are The Regulations? (1) ICH GCP says very little – it defines a CRO (1.20), the fact they may be inspected (1.29) and defines the delegation of duties (5.2) Contract Research Organization (CRO) as: "A person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or more of a sponsor's trial-related duties and functions.“ ICH GCP 1.20

What Are The Regulations? (2) Ref: ICH Q9: Quality Risk Management

Vendor Assessment Process

The Importance of Risk Assessment

QA’s role in Assessment/Evaluation  To ensure CROs conduct trials per Regulatory and Industry standards  To ensure data that is provided will be/is credible and accurate  To ensure the CRO will protect the safety, integrity and confidentiality of subjects in the trials they conduct  To ensure they can/are meet contractual obligations  To ensure they are financially viable  To conduct routine assessments at a pre-defined timeline (often every 2 years) or to assess on an ‘as need’ basis

What is the Focus of an Audit?  Review of vendor against defined scope (roles & responsibilities)  Awareness of requirements (regulations + sponsor)  Implementation of project/process (against SOPs – written processes in place)  Data protection/confidentiality  Assessment of quality activities (QC and QA)/written processes for audit  Staff qualifications (expertise in therapeutic area) and workload

Type of Vendor Audits  Initial On-site Audit  Routine Audit  For Cause Audits  Virtual Audits -Vendor Assessment/Quality Surveys

The Audit Process For Vendors Identification Operational/ Business Selection QA Audit / Assessment Positive or Negative Outcome On-going Management - Performance Assessment Re- Assessment or Audit at a defined time- line or ‘for cause’

The Audit Process for Vendors – Planning (1)  Good preparation  Carefully define audit scope  Ensure key staff are available  Review of contracts, RFIs/RFPs, project plans, scope of work, protocols etc.  Timing of the audit – proactive for any changes that need to be made  Signed Confidentiality in place  Use of contracted Auditors

The Audit Process for Vendors – Planning (2)  Draft Audit Plan and discuss audit with vendor  Send confirmation letter/  Request documents in advance from the vendor – Org Chart, list of SOPs, quality policy  Review any previous audit reports/assessments  Review websites/promotional materials  Check for any issues with vendor’s performance from project teams  Finalise Audit Agenda

The Audit Process for Vendors – Conduct Opening Meeting Introductions, purpose, scope, changes to agenda Audit Conduct Use of checklists/ interviews -discussed in next slide Auditor Review Time Review of findings, further clarification if required, categorisation of findings Exit Meeting No surprises, no lengthy discussions, next steps

General Items Audited  SOPs in place and adequate control (see next slide)  QC steps for key processes  Contracts and agreements  Subject confidentiality  Data security, transfer and protection  Staff experience and training  Facility  Equipment – maintenance, calibration and records  IT/ disaster recovery/business continuity  Document storage and archiving

SOPS  A process for pre-selection of vendors, on-going management and follow up of issues  The audit process (preparation, conduct, reporting and follow up)  A process for contracts & contract amendments in place  A list of all SOPs, templates etc. that are being used on a project (as part of the Project Plan)  A process for handover and any staff changes  Business continuity, disaster recovery plans  + All the necessary process SOPs on monitoring, data management, training etc.

The Audit Process for Vendors – Reporting & Follow Up  Audit report – prompt, clear and concise, includes timelines for response and format, copy senior management and relevant study teams, recommendations can be made?  CAPA follow up (Corrective & Preventive actions)  Issue Audit Certificate (if applicable)

What Do Inspectors/Auditors Find

EMA Inspections 2011 (1)

EMA Inspections 2011 (2)

MHRA Inspections (1)

MHRA Inspections (2)

Summary of Common Failures  Roles & responsibilities poorly defined at the contractual stage  Poor two-way communication throughout the project  Plans not in place/approved in a timely manner  Poor training on the project/ sponsor SOPs  Mixture of SOPs/forms/templates being used that have not been adequately assessed

Conclusions & Questions  Remember -> Data Integrity and Rights and Welfare of Human subjects  The sponsor cannot just sign away responsibilities and forget about them.  Good assessment/audit initially  On-going reviews/management (not micro-management, but support/partnership)  Discuss issues as they occur  Listen to your vendor